On 22 September the FDA approved a supplement to abbreviated new drug application 077328, held by Senores Pharmaceuticals, for generic risperidone. The record does not state what the supplement changed; supplements to generic applications commonly cover manufacturing, labelling alignment with the reference product, or packaging.
This is not a new indication, a new formulation for patients or a safety communication. Risperidone's efficacy, dosing and monitoring requirements are unchanged, and there is no CDSCO action associated with it.
- This is an FDA supplement to a generic risperidone application, not a new approval or indication.
- No safety signal or label warning has been announced with it.
- Prescribing and metabolic monitoring for risperidone are unchanged.
- No corresponding CDSCO action has been reported.
Why it matters
Tells prescribers the day's only psychiatric regulatory action needs no response.
Don't overread it
A generic supplement is administrative; it says nothing new about the drug's safety or effectiveness.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free